Indian National Drugs Co Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 15-11-2024
- Paid Up Capital ₹ 1.20 M
as on 15-11-2024
- Company Age 80 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.06 Cr
as on 15-11-2024
- Satisfied Charges ₹ 4.16 Cr
as on 15-11-2024
- Revenue -1.82%
(FY 2023)
- Profit -12.33%
(FY 2023)
- Ebitda -20.21%
(FY 2023)
- Net Worth 13.48%
(FY 2023)
- Total Assets -3.31%
(FY 2023)
About Indian National Drugs Co
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.20 M.
The company currently has active open charges totaling ₹5.06 Cr. The company has closed loans amounting to ₹4.16 Cr, as per Ministry of Corporate Affairs (MCA) records.
Simantika Roychowdhury, Malay Roychowdhury, Sreemoyee Roychowdhury, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232WB1944PTC011807
- Company No.
011807
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jul 1944
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Indian National Drugs Co?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Simantika Roychowdhury  | Director | 03-May-1984 | Current |
| Malay Roychowdhury | Director | 01-Apr-1988 | Current |
| Sreemoyee Roychowdhury | Director | 16-Jun-2010 | Current |
| Soumya Chowdhury | Director | 01-Apr-2021 | Current |
Financial Performance of Indian National Drugs Co.
Indian National Drugs Co Pvt Ltd, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.82% decrease. The company also saw a substantial fall in profitability, with a 12.33% decrease in profit. The company's net worth Soared by an impressive increase of 13.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indian National Drugs Co?
In 2023, Indian National Drugs Co had a promoter holding of 98.54% and a public holding of 1.46%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Pnb Housing Finance Limited Creation Date: 30 Jan 2015 | ₹5.06 Cr | Open |
Hdb Financial Services Limited Creation Date: 30 Jul 2014 | ₹3.61 Cr | Satisfied |
State Bank Of India Creation Date: 07 Jul 2006 | ₹3.00 M | Satisfied |
How Many Employees Work at Indian National Drugs Co?
Unlock and access historical data on people associated with Indian National Drugs Co, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indian National Drugs Co, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indian National Drugs Co's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
